Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

Authors

D. K. Novik (ORCID: https://orcid.org/0000-0001-5278-5557)
Claudia Djambas Khayat (ORCID: https://orcid.org/0000-0002-5584-5049)
Kateryna Vilchevska (ORCID: https://orcid.org/0000-0002-1379-0852)
Leonid Dubey (ORCID: https://orcid.org/0000-0003-1094-6708)
Alì Taher (ORCID: https://orcid.org/0000-0001-8515-2238)
Robert F. Sidonio (ORCID: https://orcid.org/0000-0002-9509-9415)
Elina Peteva
Ana Boban (ORCID: https://orcid.org/0000-0003-4284-7544)
Adlette Inati
Vladimir Vdovin
Toshko Lissitchkov

Institutions

University Hospital Centre Zagreb (HR)
Emory University (US)
University of Zagreb (HR)
Saint Joseph University (LB)
Lviv City Children's Hospital (UA)
University Hospital St. Marina (BG)
American University of Beirut Medical Center (LB)
Russian Children's Clinical Hospital (RU)
Republican Research Center for Radiation Medicine and Human Ecology (BY)
National Specialized Hospital for Active Treatment of Hematologic Diseases (BG)
Nini Hospital (LB)
Hôtel-Dieu de France (LB)
Children's Specialized Hospital (US)

Publication Details

Journal: European Journal Of Haematology
Published: 2026-01-30
DOI: https://doi.org/10.1111/ejh.70117
Primary Topic: Platelet Disorders and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

D. K. Novik, Claudia Djambas Khayat, Kateryna Vilchevska, Leonid Dubey et al.

Jan 30, 2026

European Journal Of Haematology

Platelet Disorders and Treatments

article

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

D. K. Novik, Claudia Djambas Khayat, Kateryna Vilchevska, Leonid Dubey, Alì Taher, Robert F. Sidonio, Elina Peteva, Ana Boban, Adlette Inati, Vladimir Vdovin, Toshko Lissitchkov

January 30, 2026article en

Abstract

No abstract available for this paper.

European Journal Of Haematology

University Hospital Centre Zagreb (HR), Emory University (US), University of Zagreb (HR), Saint Joseph University (LB), Lviv City Children's Hospital (UA), University Hospital St. Marina (BG), American University of Beirut Medical Center (LB), Russian Children's Clinical Hospital (RU), Republican Research Center for Radiation Medicine and Human Ecology (BY), National Specialized Hospital for Active Treatment of Hematologic Diseases (BG), Nini Hospital (LB), Hôtel-Dieu de France (LB), Children's Specialized Hospital (US)

Openalex Percentile: Top 75%

Platelet Disorders and Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis — D. K. Novik, Claudia Djambas Khayat, et al. · European Journal Of Haematology (2026) | TGRS Research Map | TGRS